Nanoform's biologics technology showcased by large pharma at drug delivery conference; Nanoenzalutamide and nanoapalutamide partnering discussions progress as planned
Company Announcement Nanoform Finland Plc May 30, 2024 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Nanoform's biologics technology showcased by large pharma at drug delivery conference; Nanoenzalutamide and nanoapalutamide partnering discussions progress as planned Manufacturing of GMP material in Project Nanoenzalutamide commenced. EU/US pivotal studies are planned to start in 4Q24, with the read-out in 1Q25. One or several license/commercial supply agreements are expected to be signed during 2H24. Fimea’s two-day inspection of our new GMP QC laboratory and new GMP